Regulation of constitutive vascular endothelial growth factor secretion in retinal pigment epithelium/choroid organ cultures: P38, nuclear factor kappaB, and the vascular endothelial growth factor receptor-2/phosphatidylinositol 3 kinase pathway

Molecular Vision

Volumn 19, Issue , 2013, Pages 281-291

  Klettner, Alexa ^a   Westhues, Daniel ^a   Lassen, Jens ^a   Bartsch, Sofia ^a,b   Roider, Johann ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Helmholtz Institute of Ophthalmology   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; STAT3 PROTEIN; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; AUTOREGULATION; CELL VIABILITY; CHOROID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INTRACELLULAR SIGNALING; NONHUMAN; ORGAN CULTURE; PARACRINE SIGNALING; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SWINE;

ANIMALS; CHOROID; CHROMONES; CINNAMATES; CYCLIC S-OXIDES; IMIDAZOLES; INDAZOLES; INDOLES; MALEIMIDES; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; NF-KAPPA B; ORGAN CULTURE TECHNIQUES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PLICAMYCIN; PYRIDINES; RETINAL PIGMENT EPITHELIUM; SIGNAL TRANSDUCTION; SUS SCROFA; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84873563991     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439-42.[PMID: 8602242].
2. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allel. Nature 1996; 380:435-9.[PMID: 8602241].
3. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E. Development of retina vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15:4738-47.[PMID: 7623107].
4. Kinnunen K, Petrovski G, Moe MC, Berta A, Kaarniranta K. Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol (Copenh) 2012; 90:299-309.[PMID: 22112056].
5. Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of macular edema. Ophthalmologica 2010; 224:Suppl. 18-15. PMID: 20714176.
6. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273:30336-43.[PMID: 9804796].
7. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 2009; 106:18751-6.[PMID: 19841260].
8. Byeon SH, Lee SC, Choi SH, Lee HK, Lee JH, Chu YK, Kwon OW. Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGFR-2/PI3K/Akt pathway. Invest Ophthalmol Vis Sci 2010; 51:1190-7.[PMID: 19834034].
9. Ford KM, Saint-Geniez M, Walshe T, Zahr A, D'Amore PA. Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci 2011; 52:9478-87.[PMID: 22058334].
10. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171:53-67.[PMID: 17591953].
11. Saint-Geniez M, Maharaj ASR, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA. Endogenous VEGF is required for visual function: Evidence for a survival role on Müller cells and photoreceptors. PLoS ONE 2008; 3:e3554.[PMID: 18978936].
12. Kilic Ü, Kilic E, Järve A, Guo Z, Spudich A, Bieber K, Barzena U, Bassetti CL, Marti HH, Hermann DM. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating Erk1/2 and Akt pathways. J Neurosci 2006; 26:12439-46.[PMID: 17135405].
13. Pagès G, Pouyssegur J. Transcriptional regulation of Vascular Endothelial Growth Factor gene - a concert of activating factors. Cardiovasc Res 2005; 65:564-73.[PMID: 15664382].
14. Jósko J, Mazurek M. Transcription factors having impact on VEGF gene expression in angiongenesis. Med Sci Monit 2004; 10:RA89-98.[PMID: 15039660].
15. Pagès G, Berra E, Milanini J, Levy AP, Pouyssegur J. Stress activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor (VEGF) mRNA stability. J Biol Chem 2000; 275:26484-91.[PMID: 10849421].
16. Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res 2007; 84:812-22.[PMID: 17331500].
17. Klettner A, Roider J. Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases. Graefes Arch Clin Exp Ophthalmol 2009; 247:1487-92.[PMID: 19603178].
18. Kunchithapautham K, Rohrer B. Sublytic membrane-attackcomplex (MAC) activation alters regulated rather than constitutive vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelium monolayers. J Biol Chem 2011; 286:23717-24.[PMID: 21566137].
19. Klettner A, Roider J. Comparison of Bevacizumab, Ranibizumab and Pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008; 49:4523-7.[PMID: 18441313].
20. Deudero JJ, Caramelo C, Castallanos M, Neria F, Fernandez-Sanchez R, Calabia O, Penate S, Gonzales-Pacheco F. Induction of hypoxia-inducible factor 1alpha gene expression by vascular endothelial growth factor. J Biol Chem 2008; 283:11435-44.[PMID: 18305118].
21. Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, Bartek J. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 2008; 7:2553-61.[PMID: 18719373].
22. Miura Y, Klettner A, Noelle B, Hasselbach H, Roider J. Change of morphological characteristics of retinal pigment epithelium cells during cultivation of retinal pigment epithelium-choroid perfusion tissue culture. Ophthalmic Res 2010; 43:122-33.[PMID: 19887877].
23. Minuth WW, Steiner P, Strehl R, Schumacher K, de Vries U, Kloth S. Modulation of cell differentiation in perfusion culture. Exp Nephrol 1999; 7:394[PMID: 10559637].
24. Klettner A, Koinzer S, Waetzig V, Herdegen T, Roider J. Deferoxamine mesylate is toxic for retinal pigment epithelium cells, and its toxicity is mediated by p38. Cutan Ocul Toxicol 2010; 29:122-9.[PMID: 20380623].
25. Klettner A. Roider J. Mechanisms of Pathological VEGF Production in the Retina and Modification with VEGF-Antagonists. In: Stratton R, Hauswirth W, Gardner T, editors. Oxidative Stress in Applied Basic Research and Clinical Practise: Studies on Retinal and Choroidal Disorders. Humana Press; 2012; p. 277-307.
26. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F, Duhame L, Charon D, Kirilovsky J. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 1991; 266:15771-81.[PMID: 1874734].
27. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinosiytol 3-kinase 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269:5241-8.[PMID: 8106507].
28. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: A smallmolecule inhibitor of STAT3 activation and dimerisation. Chem Biol 2006; 13:1235-42.[PMID: 17114005].
29. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS, Park JW. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001; 61:947-54.[PMID: 11286986].
30. Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, Fukazawa T, Hayashi H. Discovery of quinazolines as a novel structure class of potent inhibitors of NF-kB activation. Bioorg Med Chem 2003; 11:383-91.[PMID: 12517433].
31. Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, Kharel MK, Guo H, Marsh JL, Thompson LM, Mahishi L, Ahuja P, MacLellan WR, Geschwind DH, Coppola G, Rohr J, Ratan RR. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci 2011; 31:6858-70.[PMID: 21543616].
32. Lisnock J, Tebben A, Frantz B, O'Neill EA, Croft G, O'Keefe SJ, Li B, Hacker C, de Laszlo S, Smith A, Libby B, Liverton N, Hermes J, LoGrasso P. Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry 1998; 37:16573-81.[PMID: 9843424].
33. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996; 56:3540-5.[PMID: 8758924].
34. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351:95-105.[PMID: 10998351].
35. Hardenbol P, Van Dyke MW. In vitro inhibition of c-myc transcription by mithramycin. Biochem Biophys Res Commun 1992; 185:553-8.[PMID: 1535193].
36. De Niero M, Al-Halafi A, Al-Mohanna FH, Alsmadi O, Al-Mohanna FA. Pleiotropic effects of YC-1 selectively inhibit pathological retina neovascularisation and promote physiological revascularization in a mouse model of oxygeninduced retinopathy. Mol Pharmacol 2010; 77:348-67.[PMID: 20008515].
37. Roberts NA, Marber MS, Avkiran M. Specificity of action of bisindolylmaleimide protein kinase C inhibitors: do they inhibit the 70 kDa ribosomal S6 kinase in cardiac myocytes? Biochem Pharmacol 2004; 68:1923-8.[PMID: 15476663].
38. Kernt M, Thiele S, Neubauer AS, Koenig S, Hirneiss C, Haritoglou C, Ulbig MW, Kampik A. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. Retina 2012; 32:1652-63.[PMID: 22466477].
39. Yafai Y, Tang XM, Niemeyer M, Nishiwaki A, Lange J, Wiedermann P, King A, Yasukawa T, Eichler W. Antiangiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. Eur J Pharmacol 2011; 666:12-8.[PMID: 21620822].
40. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U. Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the Retina after Intravitreal Injection in the Monkey. Invest Ophthalmol Vis Sci 2007; 48:2814-23.[PMID: 17525217].
41. Chen Z, Han ZC. Stat3: A critical transcription activator in angiogenesis. Med Res Rev 2008; 28:185-200.[PMID: 17457812].
42. Niu G, Wrigth KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21:2000-8.[PMID: 11960372].
43. Zhang P, Wang Y, Hui Y, Hu D, Wang H, Zhou J, Du H. Inhibition of VEGF expression by targeting HIF-1α with small interference RNA in human RPE cells. Ophthalmologica 2007; 221:411-7.[PMID: 17947829].
44. Greenberger S, Adini I, Boscilo E, Mulliken JB, Bischoff J. Targeting NF-kB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 2010; 13:327-35.[PMID: 20872175].
45. Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E. VEGF expression in human macrophages is NFkB-dependent: studies using adenoviruses expression the endogenous NF-kB inhibitor IkBα and a kinase-defective form of IkB kinase 2. J Cell Sci 2003; 116:665-74.[PMID: 12538767].
46. Larrayoz IM, Hunag JD, Lee JW, Pascual I, Rodriguez I. 7-Ketochol-induced inflammation: Involvement of multiple kinase signaling pathways via NFkB but independently of reactive oxygen species formation. Invest Ophthalmol Vis Sci 2010; 51:4942-55.[PMID: 20554621].
47. Hayden MS, Ghosh S. NF-kB in immunobiology. Cell Res 2011; 21:223-44.[PMID: 21243012].
48. Salminen A, Kaarniranta K. Regulation of the aging process by autophagy. Trends Mol Med 2009; 15:217-24.[PMID: 19380253].
49. Salminen A, Kaarniranta K. NF-kB Signaling in the Aging Process. J Clin Immunol 2009; 29:397-405.[PMID: 19408108].
50. Kaarniranta K, Salminen A. Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors. J Mol Med 2009; 87:117-23.[PMID: 19009282].
51. Forster R, Ancian P, Fredholm M, Simianer H, Whitelow B. The minipig as a platform for new technologies in toxicology. J Pharmacol Toxicol Methods 2010; 62:227-35.[PMID: 20685311].
52. Saint-Geniez M, Maldonado A, D'Amore P. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci 2006; 47:3135-42.[PMID: 16799060].
53. Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res 2010; 29:144-68.[PMID: 20044062].
54. Notting IC, Missotten GS, Sijmons B, Boonman ZF, Keunen JE, van der Pluijm G. Angiogenic profile of uveal melanoma. Curr Eye Res 2006; 31:775.[PMID: 16966150].
55. Schroedl F, Brehmer A, Neuhuber WL, Kruse FE, May CA, Cursiefen C. The normal human choroid is endowed with a significant number of lymphatic vessel endothelial hyalronate receptor 1 (LYVE-1)-positive macrophages. Invest Ophthalmol Vis Sci 2008; 49:5222-9.[PMID: 18689706].
56. Apte RS. Regulation of angiogenesis by macrophages. Adv Exp Med Biol 2010; 664:15-9.[PMID: 20237997].
57. Lin HH, Faunce DE, Stacey M, Terajewicz A, Nakamura T, Zhang-Hoover J, Kerley M, Mucenski ML, Gordon S, Stein-Streilein J. The macrophage F4/80 is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J Exp Med 2005; 201:1615-25.[PMID: 15883173].
58. Nagineni CN, Kommineni VK, William A, Detrick B, Hooks JJ. Regulation of VEGF expression in human retinal cells by cytokines: Implications for the role of inflammation in age-related macular degeneration. J Cell Physiol 2012; 227:116-26.[PMID: 21374591].
59. Kvanta A. Expression and regulation of vascular endothelial growth factor in choroidal fibroblasts. Curr Eye Res 1995; 14:1015-20.[PMID: 8585929].
60. Shiose S, Hata Y, Noda Y, Sassa Y, Takeda A, Yoshikawa H, Fujisawa K, Kubota T, Ishibashi T. Fibrinogen stimulates in vitro angiogenesis by choroidal endothelial cells via autokrine VEGF. Graefes Arch Clin Exp Ophthalmol 2004; 242:777-83.[PMID: 15103470].
61. Hoffmann S, Friedrichs U, Eichler W, Rosenthal A, Wiedermann P. Advanced glycation end products induces choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro. Graefes Arch Clin Exp Ophthalmol 2002; 240:996-1002.[PMID: 12483322].
62. Balaiya S, Khetpal V, Chalam KV. Hypoxia initiates sirtuin1-mediated vascular endothelial growth factor activation in choroidal endothelial cells through hypoxia inducible factor-2α. Mol Vis 2012; 18:114-20.[PMID: 22275802].
63. 2 activity. Mol Vis 2004; 10:341-50.[PMID: 15162095].
64. Doronzo G, Viretto M, Russo I, Mattiello L, Anfossi G, Trovatti M. Effects of glucose on vascular endothelial growth factor synthesis and secretion in aortic vascular smooth muscle cells from obese and lean zucker rats. Int J Mol Sci 2012; 13:9478-88.[PMID: 22949809].
65. Demyantes S. Kaun C, Rychli K, Pfaffenberger S, Kastl SP, Hohensinner PJ, Rega G, Katsaros KM, Afonyushkin T, Bochkov VN, Paireder M, Huk I, Maurer G, Huber K, Wojta J. Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependentpathways and is attenuated by interferon-γ. Brain Res Cardiol 2011; 106:217-31.
66. Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, D'Amore P. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003; 264:275-88.[PMID: 14623248].
67. Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M. Up-regulation of vascular endothelial growth factor and down-regulation fo pigment epithelium-derived factor messenger ribonucleic acid levels in leptin-exposed cultured retinal pericytes. Int J Tissue React 2002; 24:137-42.[PMID: 12779248].
68. Vidro EK, Gee S, Unda R, Ma JX, Tsin A. Glucose and TGFbeta2 modulate the viability of cultured human retinal pericytes and their VEGF release. Curr Eye Res 2008; 33:984-93.[PMID: 19085381].
69. Kim I, Ryan AM, Rohan R, Amano S, Agular S, Miller JW, Adamis AP. Constitutive expression of VEGF, VEGRR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999; 40:2115-21.[PMID: 10440268].
70. Ishibashi T, Hata Y, Yoshikawa H, Nakagawa K, Sueishi K, Inomata H. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997; 235:159-67.[PMID: 9085111].
71. Stitt AW, Simpson DA, Boocock C, Gardinger TA, Murphy GM, Archer DB. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol 1998; 186:306-12.[PMID: 10211121].